Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Nele Van Der Steen; Christophe Deben; Vanessa Deschoolmeester; An Wouters; Filip Lardon; Christian Rolfo; Paul Germonpré; Elisa Giovannetti; Godefridus J Peters; Patrick Pauwels

doi:https://doi.org/10.5306/wjco.v7.i6.425

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Nele Van Der Steen, Christophe Deben, Vanessa Deschoolmeester, An Wouters, Filip Lardon, Christian Rolfo, Paul Germonpré, Elisa Giovannetti, Godefridus J Peters, Patrick Pauwels

Medical oncology laboratory (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.

METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.

RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.

CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

Original language	English
Pages (from-to)	425-432
Number of pages	8
Journal	World journal of clinical oncology
Volume	7
Issue number	6
DOIs	https://doi.org/10.5306/wjco.v7.i6.425
Publication status	Published - 10 Dec 2016

Access to Document

https://doi.org/10.5306/wjco.v7.i6.425

Cite this

Van Der Steen, N., Deben, C., Deschoolmeester, V., Wouters, A., Lardon, F., Rolfo, C., Germonpré, P., Giovannetti, E., Peters, G. J., & Pauwels, P. (2016). Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World journal of clinical oncology, 7(6), 425-432. https://doi.org/10.5306/wjco.v7.i6.425

@article{03e79b541800428d800446365139b979,

title = "Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer",

abstract = "AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.",

author = "{Van Der Steen}, Nele and Christophe Deben and Vanessa Deschoolmeester and An Wouters and Filip Lardon and Christian Rolfo and Paul Germonpr{\'e} and Elisa Giovannetti and Peters, {Godefridus J} and Patrick Pauwels",

year = "2016",

month = dec,

day = "10",

doi = "https://doi.org/10.5306/wjco.v7.i6.425",

language = "English",

volume = "7",

pages = "425--432",

journal = "World journal of clinical oncology",

issn = "2218-4333",

publisher = "Baishideng Publishing Group",

number = "6",

}

Van Der Steen, N, Deben, C, Deschoolmeester, V, Wouters, A, Lardon, F, Rolfo, C, Germonpré, P, Giovannetti, E , Peters, GJ & Pauwels, P 2016, 'Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer', World journal of clinical oncology, vol. 7, no. 6, pp. 425-432. https://doi.org/10.5306/wjco.v7.i6.425

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. / Van Der Steen, Nele; Deben, Christophe; Deschoolmeester, Vanessa et al.
In: World journal of clinical oncology, Vol. 7, No. 6, 10.12.2016, p. 425-432.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Better to be alone than in bad company

T2 - The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

AU - Van Der Steen, Nele

AU - Deben, Christophe

AU - Deschoolmeester, Vanessa

AU - Wouters, An

AU - Lardon, Filip

AU - Rolfo, Christian

AU - Germonpré, Paul

AU - Giovannetti, Elisa

AU - Peters, Godefridus J

AU - Pauwels, Patrick

PY - 2016/12/10

Y1 - 2016/12/10

N2 - AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

AB - AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

U2 - https://doi.org/10.5306/wjco.v7.i6.425

DO - https://doi.org/10.5306/wjco.v7.i6.425

M3 - Article

C2 - 28008383

SN - 2218-4333

VL - 7

SP - 425

EP - 432

JO - World journal of clinical oncology

JF - World journal of clinical oncology

IS - 6

ER -